SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 762.36+3.4%3:24 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: The Ox7/31/2017 10:08:44 AM
   of 3559
 
Law360, New York (July 27, 2017, 7:51 PM EDT) -- The Federal Circuit said Thursday a Regeneron Pharmaceuticals Inc. patent for a genetically modified mouse was unenforceable because of the biotechnology company’s inequitable conduct at the patent office, upholding a lower court’s decision.

A three-judge panel affirmed 2-1 a 2015 ruling from U.S. District Judge Katherine B. Forrest in an infringement suit against Merus NV. The court said Judge Forrest did not abuse her discretion in finding the patent unenforceable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News